Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
77
Frequently Asked Questions
What is Market Cap of Lineage Cell Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Lineage Cell Therapeutics Inc market cap is $260.49M.
What is the 52-week high for Lineage Cell Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Lineage Cell Therapeutics Inc 52 week high is $2.09 as of October 10, 2026.
What is the 52-week low for Lineage Cell Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Lineage Cell Therapeutics Inc 52 week low is $0.8823 as of October 10, 2026.
What is Lineage Cell Therapeutics Inc stock price today?
Lineage Cell Therapeutics Inc stock price today is $0.994.
What was Lineage Cell Therapeutics Inc stock price yesterday?
Lineage Cell Therapeutics Inc stock price yesterday was $1.03.
What is the PE ratio of Lineage Cell Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Lineage Cell Therapeutics Inc's P/E ratio is -5.39.
What is the Price-to-Book ratio of Lineage Cell Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Lineage Cell Therapeutics Inc P/B ratio is 4.1269.
What is the 50-day moving average of Lineage Cell Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Lineage Cell Therapeutics Inc 50-day moving average is $1.05.
How many employees does Lineage Cell Therapeutics Inc have?